HomeNews & TopicsResearchWorld first: direct-to-brain delivery of therapeutic in Parkinson's disease using focused ultrasound...

World first: direct-to-brain delivery of therapeutic in Parkinson’s disease using focused ultrasound is safe

Published on

A team of researchers from Sunnybrook Health Sciences Centre and University Health Network (UHN) are the first in the world to demonstrate that focused ultrasound technology can safely be used to deliver a therapeutic to targeted brain regions in patients with Parkinson’s disease (PD).

The leading-edge study has been published in Movement Disorders.

“Our early findings are an exciting and critical first step in less invasive direct-to-brain delivery of therapeutics to key areas of the brain important in the development and progression of Parkinson’s disease,” says Dr. Nir Lipsman, the study’s co-principal investigator and director of Sunnybrook’s Harquail Centre for Neuromodulation. “Current management strategies for Parkinson’s include medications and more invasive neurosurgery. Focused ultrasound is a less invasive, targeted approach that could change the way brain disorders are treated in the future.”

Low intensity MRI-guided focused ultrasound technology uses ultrasound waves to breach the blood-brain barrier, a layer of cells that protects the brain from toxins but can also block potentially helpful medications from getting where they need to go. The opening in the barrier, which closes within hours of the procedure, allows the therapy to pass and reach targeted brain region with millimetre accuracy.

Typically, treatments are unable to cross the blood-brain barrier because compounds are too large. In some cases, open brain surgery is required to help manage PD symptoms.

There is currently no cure for Parkinson’s, which is a common and progressive brain disorder that causes difficulties with movement and numerous disabling symptoms which dramatically impact a patient’s quality of life. Symptoms vary, and can progress at a different rate for each individual.

Study researchers investigated the delivery of an enzyme, glucocerebrosidase, to the putamen which is a key structure in the brain related to movement. Glucocerebrosidase may help to prevent buildup of the protein alpha-synuclein, a key indicator of PD that leads to unhealthy brain cells and neurodegeneration. In Parkinson’s, the enzyme can be defective and result in PD symptoms. Enzyme replacement therapy could be one approach to reduce or prevent neurodegeneration in PD.

The Phase I trial included four patients diagnosed with early-stage Parkinson’s disease with an average age of 54 years. Participants received three doses of the therapeutic and application of focused ultrasound every two weeks to the side of the brain most affected by the disease. They were followed for three and six months.

“The Phase I trial offered a hint of potential improvement in symptoms following treatment but this requires further study. Any side effects, such as involuntary movements, were only temporary, and none were severe,” says Dr. Lorraine Kalia, co-principal investigator and a neurologist and senior scientist at the Krembil Brain Institute, part of UHN. “It is still very early in the research, but with our first-in-the-world study findings, we are making much needed progress in the development of innovative treatments for people with Parkinson’s disease.”

The Sunnybrook and UHN researchers have launched a Phase I/II clinical trial continuing the team’s investigation.

“The upcoming trial will further explore low intensity MRI-guided focused ultrasound and targeting enzyme replacement therapy to both sides of the brain. The ultimate goal is to improve the delivery of therapeutics to the brain with the hope of improved symptoms or slowed progression of Parkinson’s disease,” says Dr. Suneil Kalia, co-principal investigator and a neurosurgeon and scientist at UHN.

“There is robust data in both preclinical and clinical studies demonstrating that glucocerebrosidase replacement is a promising disease-modifying therapy in Parkinson’s disease. The next step is to better understand the biologic effects of the treatment with further research,” says Dr. Ying Meng, the study’s first author and neurosurgery resident at Sunnybrook.

 

Latest articles

Common drug interactions with over-the-counter medications

TJ, a 45-year-old male with symptoms of a common cold (sore throat, headache, runny...

Easing the Transition to the Cloud. Modernizing made simple with integration support.

Across Canada, most hospitals and healthcare authorities recognize the need to modernize their systems....

Rovolutionizing geriatric care: Meet Canada’s leading Universal Health Hub (UHH)

Universal Health Hub (UHH) is the only Health Care Organization in Canada which is...

National efforts to guide safe, effective, and equitable use of opioids for quality pain management in children

No one should experience untreated pain. Yet, in Canada, two out of three children...

More like this

The Connector

In a world where an implantable electrode can reduce the number and intensity of...

How AI can reduce turn around times for clinical trial contracts

Unity Health Toronto is one of the first hospitals in Canada to work with...

Navigating the fallout: 23andMe’s data breach and the ethics of consumer genetic testing

By unlocking secrets encrypted within our DNA, genetic testing has become a powerful tool,...

Obesity a risk factor for stillbirth, especially at term

Obesity is a risk factor for stillbirth, and the risk increases as pregnancy advances...

Researching a new treatment for sepsis

For people who are in the intensive care unit (ICU) with a serious health...

Health care inequities behind shorter life spans for Inuit from Nunavik, Quebec, with lung cancer

People living in the Inuit region of Nunavik in northern Quebec die earlier after...